Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 20,541

Document Document Title
WO/2021/070132A1
Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula I as follows: Formula I wherein R1, R2, R3,...  
WO/2021/063880A1
The present invention relates to a process for the preparation 2-chloro-1-(2-chlorothiazol-5-yl)ethanone.  
WO/2021/062246A1
Compounds are provided herein, as well as related preparations, compositions and methods for treating diseases and/or disorders that would benefit from the same such as congenital adrenal hyperplasia (CAH).  
WO/2021/058969A1
A composition for imaging a biological tissue or fluid comprising a compound of formula (A) and a biologically acceptable diluent or carrier, (A) wherein X represents one of a nitrogen atom, an oxygen atom, a sulphur atom, a phosphorus a...  
WO/2021/061801A1
A genus of bicyclic inhibitors of CBX chromodomains is disclosed. The compounds are of the following genus: The compounds inhibit CBX proteins and, as a consequence, they are useful for treating prostate cancer, ovarian cancer, and B-cel...  
WO/2021/062318A1
Provided herein are compounds of Formula (I) and Formula (II) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical composition...  
WO/2021/053403A1
The invention provides a compound of formula (I) and processes for the manufacture of such compounds, related intermediates, compositions comprising such compounds and the use of such compounds as cytidine triphosphate synthase 1 inhibit...  
WO/2021/055890A1
Disclosed herein are controlled release compositions comprising riluzole and the uses thereof.  
WO/2021/048284A1
The present invention relates to a chemical compound having the general formula (I), wherein R1 is a phenyl group and R2 is a meta-substituted phenyl group; and RTA is a substituted or unsubstituted thiazole ring. The invention also rela...  
WO/2021/049522A1
A compound represented by formula (I) or formula (II) has a pest control effect. (In the formulae, Q1 represents a pyrazine ring or the like; G1 represents a nitrogen atom or a carbon atom; X1 represents an alkyl group or the like; m rep...  
WO/2021/043994A1
The present invention relates to an azolium compound of formula (I) and to its use as a precursor of the active catalytic species (carbene) for click chemistry reactions in water.  
WO/2021/042410A1
Disclosed are a selective butyrylcholinesterase inhibitor having general formula (I) or a pharmaceutically acceptable salt thereof, a preparation method therefor, and use thereof. By testing the efficacy of treatment of Alzheimer's disea...  
WO/2021/032857A1
The invention provides the imidazole, oxazole and thiazole compounds and use thereof in methods for treating a disease or a disorder, such as infectious diseases and cancer, wherein inhibition of sphingosine-1-phosphate lyase is benefici...  
WO/2020/247819A3
Described herein is a compound of Formula I or a pharmaceutically acceptable salt thereof: wherein Ring A R1, R2, a, b, and n are as defined herein. Also described is a method of treating a subject having a disorder in need of treatment,...  
WO/2021/027045A1
An anti-tumour compound based on JWA gene activation and HER2 degradation, a preparation method therefor, and a use thereof. The anti-tumour compound is the compound of formula I. The preparation method is using two compounds to synthesi...  
WO/2021/028518A1
The invention relates to a new process for preparing 2-(phenylimino)-3-alkyl-1,3-thiazolidin-4-ones of the general formula (I), wherein Y1, Y2, R1, R2 and R3 have the meanings indicated in the description.  
WO/2021/028375A1
The present invention relates to the technical field of crop protection. More specifically, the present invention relates to benazolin-choline and to compositions (formulations) comprising benazolin-choline. The invention also relates to...  
WO/2021/028810A1
The present invention relates to certain compounds, their use in therapy, as well as to pharmaceutical compositions including said compounds. Specifically, the invention relates to certain compounds and pharmaceutical compositions includ...  
WO/2021/024253A1
This invention is directed to a method of oxidation of 5-chloro-2-((3,4,4-trifluorobut-3- en- 1-yl)thio)- lλ3,3λ2-thiazole and analogs thereof to the corresponding sulfone, using an oxidant and a metal oxide-based catalyst.  
WO/2021/026179A1
The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositio...  
WO/2021/024260A1
The technology disclosed herein concerns compounds capable of binding to CB1Rs in the periphery and not in the CNS.  
WO/2021/019051A1
The present invention relates to novel inhibitors of adipose triglyceride lipase (ATGL) having an improved inhibitory activity against human ATGL (hATGL) as well as pharmaceutical compositions comprising these inhibitors, and their thera...  
WO/2021/010337A1
The invention is the light-emitting compound represented by formula (1), or a salt thereof.  
WO/2021/010340A1
The present invention is a luminescent compound represented by formula (1) or a salt thereof. (In formula (1), k represents 0 or 1; at least one of X and Y represents an optionally substituted heterocyclic group containing a nitrogen ato...  
WO/2021/007661A1
The current application relates to cannabinoid derivatives of formula (I) and pharmaceutical compositions comprising the same. The cannabinoid derivative can be used for the treatment of diseases associated with cannabinoid receptor such...  
WO/2021/010331A1
The present invention is a light-emitting compound represented by formula (1) or a salt thereof.  
WO/2021/007663A1
This disclosure relates to cannabinoid derivatives of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in treating or preventing a diseases associated with a cannabinoid receptor ...  
WO/2021/005082A1
The invention relates to a process for preparing 2-(phenylimino)-1,3-thiazolidin-4-ones of the general formula (I), wherein Y1, Y2, R1, R2 and R3 have the meanings indicated in the description.  
WO/2021/005081A1
The invention relates to a process for preparing 2-(phenylimino)-1,3-thiazolidin-4-ones of the general formula (I), wherein Y1, Y2, R1, R2 and R3 have the meanings indicated in the description.  
WO/2021/004487A1
A thiazolidinedione derivative having the structure shown in formula (I) and a pharmaceutical composition comprising same, the definitions of each group and substituent being as described in the description. Also provided is a use of the...  
WO/2021/001825A1
The present invention provides novel inhibitors of cystathionin gamma synthase (CGS), their use as selective and non-selective herbicides, agricultural and non-agricultural herbicides, herbicides in integrated pest management, herbicides...  
WO/2020/257940A1
The present application provides furosemide analogues of the general formula Z having activity as anti-Aβ aggregation agents and/or as inhibitors of Aβ induced neuroinflammation. Formula Z These compounds are useful in preventing, dela...  
WO/2020/262648A1
The present invention provides a compound that has an excellent pest-controlling effect and that is represented by formula (I) [in the formula, L represents an oxygen atom or CH2, E represents a C2-C10 chain hydrocarbon group or the like...  
WO/2020/258972A1
The present invention provides a brand-new hydrazone amide derivative and an application thereof in preparation of medicaments for preventing and treating alopecia. The structural formula of the hydrazone amide derivative is as shown for...  
WO/2020/009492A9
The present specification provides a compound represented by chemical formula 1 and an organic light emitting diode comprising same.  
WO/2020/010143A8
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein, useful to tre...  
WO/2020/258893A1
A formulation of conjugates of tubulysin analogs with a cell-binding molecule having a structure represented by Formula (I), wherein T, L, m, n, -----, R 1, R 2, R 3, R 4, R 5, R 6, R 7, R 8, R 9, R 10, R 11, R 12, and R 13 are as define...  
WO/2020/258971A1
Provided are a new class of hydrazone amide derivatives and the use thereof in the preparation of anti-osteoporosis drugs, wherein the structural formula of the hydrazone amide derivative is as shown in formula (I), and same are a new cl...  
WO/2020/250223A1
The invention relates to a novel substituted amino acids, agricultural compositions comprising the novel substituted amino acids, and their use for controlling undesired plant growth alone or in combination with crop protection agents su...  
WO/2020/244452A1
A heterocyclic derivative having a β2 receptor agitation and M receptor antagonistic activity and medical use thereof. The heterocyclic derivative is a compound represented by general formula (I) or a mesomer, racemate, enantiomer, dias...  
WO/2020/247819A2
Described herein is a compound of Formula I or a pharmaceutically acceptable salt thereof: wherein Ring A R1, R2, a, b, and n are as defined herein. Also described is a method of treating a subject having a disorder in need of treatment,...  
WO/2020/245665A1
Compounds of formula (I) wherein ring B is selected from the group consisting of Formula (B-a) and Formula (B-bc) as human cytidine triphosphate synthase 1 ( CTPS1) inhibitors for the treatment of proliferative diseases, such as e.g. can...  
WO/2020/240178A1
A compound, e.g. a diamine ligand, represented by the following general formula (1): (Formula (1)) wherein each * represents an asymmetric carbon atom; X represents a group selected from one of an ester (e.g. a t-butyl ester); a thioeste...  
WO/2020/233618A1
Provided in the present invention are inhibitors for programmed cell necrosis, a preparation method therefor and a use thereof. Specifically, provided in the present invention are a compound represented by formula I and a composition com...  
WO/2020/232655A1
Presented is an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosure, it is possible to provide an organic elect...  
WO/2020/230132A1
The present invention provides herbicidal compositions and use thereof as for controlling plant growth.  
WO/2020/232445A1
The disclosure is directed, inter alia, to compounds and compositions that modulate pyrimidine nucleotide biosynthetic pathways, such as the pyrimidine nucleoside salvage pathway and the pyrimidine de novo pathway, and to their use in tr...  
WO/2020/232255A1
Compounds described herein may be used for the treatment of neurodegenerative diseases linked to protein misfolding, including prion diseases, Alzheimers' disease, Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), and als...  
WO/2020/231496A1
Provided herein, are methods of making a thi azoline anti-hyperalgesic, Compound 1, and polymorphs, thereof. The methods described herein use inexpensive reagents and are capable of providing Compound 1 in commercial-scale quantities. Al...  
WO/2020/229688A1
A pharmaceutical composition or combination product comprising certain thiazoles in combination with certain protein kinase inhibitors, in particular phosphatidylinositol-4,5-bisphosphate 3-kinase inhibitors (PI3K), such as buparlisib. T...  

Matches 1 - 50 out of 20,541